Related Experiment Video
Updated: Mar 2, 2026
08:33
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
1.9K
Pregabalin and lamotrigine in central poststroke pain: A pilot study
Jayantee Kalita1, Satish Chandra1, Usha Kant Misra1
1Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Neurology India
|May 11, 2017
Summary
Pregabalin and lamotrigine effectively treat central poststroke pain (CPSP), with similar efficacy. However, lamotrigine caused more side effects, leading to withdrawal in some patients.
Area of Science:
- Neurology
- Pharmacology
Background:
- Central poststroke pain (CPSP) is a debilitating condition often lacking comparative treatment studies.
- Class I drugs are frequently used, but evidence on their comparative efficacy and safety in CPSP is limited.
Purpose of the Study:
- To compare the safety and efficacy of pregabalin and lamotrigine for managing central poststroke pain (CPSP).
Main Methods:
- A randomized study involving 30 patients with CPSP (Visual Analog Scale score ≥50 mm).
- Patients received either oral pregabalin or oral lamotrigine.
- Outcomes included pain reduction (VAS), allodynia, and anxiety/depression scores (HAD) at 3 months, along with adverse reactions.
Main Results:
- Both pregabalin and lamotrigine significantly improved VAS, allodynia, and HAD scores from baseline.
- No significant difference in efficacy was observed between the two drugs.
- Lamotrigine was associated with a higher incidence of adverse reactions, specifically skin rash, leading to withdrawal in three patients.
Conclusions:
- Pregabalin and lamotrigine demonstrate comparable efficacy in treating central poststroke pain (CPSP).
- Lamotrigine carries a higher risk of adverse effects, including skin rash, necessitating drug discontinuation in some cases.
Related Concept Videos
01:25Analgesia and Pain Management
2.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.4K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K